File(s) under embargo
Reason: 12 month embargo from publication
until file(s) become available
Genome-wide gene-by-smoking interaction study of Chronic Obstructive Pulmonary Disease
journal contributionposted on 26.06.2020, 14:09 by Woori Kim, Dmitry Prokopenko, Phuwanat Sakornsakolpat, Brian D. Hobbs, Sharon M. Lutz, John E. Hokanson, Louise Wain, carl Melbourne, nick Shrine, Martin Tobin, Edwin K. Silverman, Michael H. Cho, Terri H. Beaty
Risk for Chronic Obstructive Pulmonary Disease (COPD) is determined by both cigarette smoking and genetic susceptibility, but little is known about gene-by-smoking interactions. We performed a genome-wide association analysis of 179,689 controls and 21,077 COPD cases from UK Biobank subjects of European ancestry, considering genetic main effects and gene-by-smoking interaction effects simultaneously (2-degree-of-freedom (2df) test) as well as interaction effects alone (1-degree-of-freedom (1df) interaction test). We sought to replicate significant results in the COPDGene study and SpiroMeta Consortium. We considered two smoking variables: (1) ever/never and (2) current/non-current. In the 1df interaction test, we identified one genome-wide significant locus on 15q25.1 (CHRNB4) and identified PI*Z allele (rs28929474) SERPINA1 and 3q26.2 (MECOM) in an analysis of previously reported COPD loci. In the 2df test, most of the significant signals were also significant for genetic marginal effects, aside from 16q22.1 (SMPD3) and 19q13.2 (EGLN2). The significant effects at 15q25.1 and 19q13.2 loci, both previously described in prior genome-wide association studies of COPD or smoking, but not 16q22.1 or 3q26.2, were replicated in the COPDGene and SpiroMeta. In our study, we identified interaction effects at previously reported COPD loci, however, we failed to identify novel susceptibility loci.